The Genetics of NAFLD

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2013 Sep 25

PMID 24061205

Citations 152

Authors

Quentin M Anstee

Christopher P Day

Affiliations

Soon will be listed here.

Abstract

NAFLD is a disease spectrum ranging from simple steatosis, through steatohepatitis to fibrosis and, ultimately, cirrhosis. This condition is characterized by considerable interpatient variability in terms of severity and rate of progression: although a substantial proportion of the population is at risk of progressive disease, only a minority experience associated morbidity. As such, NAFLD is best considered a complex disease trait resulting from environmental exposures acting on a susceptible polygenic background and comprising multiple independent modifiers. Much ongoing research is focused on identifying the genetic factors that contribute to NAFLD pathogenesis. This Review describes the current status of the field, discussing specific genetic and epigenetic modifiers, including the mechanisms through which genes identified by genome-wide association studies, including PNPLA3, influence disease progression.

Citing Articles

Association between single nucleotide polymorphisms in PNPLA3, TM6SF2 and MBOAT7 genes and markers of cancer aggressiveness in a Sri Lankan NASH-related HCC cohort.

Samarasinghe S, Hewage A, Siriwardana R, Tennekoon K, Niriella M, De Silva S BMC Gastroenterol. 2025; 25(1):151.

PMID: 40065199 PMC: 11892176. DOI: 10.1186/s12876-025-03738-w.

Causal relationships between three plasma proteins and non-alcoholic fatty liver disease, mediated by Epstein-Barr virus EA-D antibody levels: a mendelian randomization study.

Ming R, Wu H, Wu Z Sci Rep. 2024; 14(1):25644.

PMID: 39463412 PMC: 11514233. DOI: 10.1038/s41598-024-77105-2.

The Multifunctional Role of KCNE2: From Cardiac Arrhythmia to Multisystem Disorders.

Song M, Zhuge Y, Tu Y, Liu J, Liu W Cells. 2024; 13(17.

PMID: 39272981 PMC: 11393857. DOI: 10.3390/cells13171409.

ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.

Liu Y, Kimura M, Li X, Sulc J, Wang Q, Rodriguez-Lopez S J Hepatol. 2024; 82(2):174-188.

PMID: 39181211 PMC: 11741923. DOI: 10.1016/j.jhep.2024.08.009.

Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay.

Arvanitakis K, Chatzikalil E, Kalopitas G, Patoulias D, Popovic D, Metallidis S J Clin Med. 2024; 13(14).

PMID: 39064282 PMC: 11278502. DOI: 10.3390/jcm13144243.

References

Pirazzi C, Adiels M, Burza M, Mancina R, Levin M, Stahlman M . Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol. 2012; 57(6):1276-82. DOI: 10.1016/j.jhep.2012.07.030. View

Altshuler D, Daly M, Lander E . Genetic mapping in human disease. Science. 2008; 322(5903):881-8. PMC: 2694957. DOI: 10.1126/science.1156409. View

Willer C, Sanna S, Jackson A, Scuteri A, Bonnycastle L, Clarke R . Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008; 40(2):161-9. PMC: 5206900. DOI: 10.1038/ng.76. View

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

Ginsberg H, Le N, Goldberg I, Gibson J, Rubinstein A, Norum R . Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78(5):1287-95. PMC: 423815. DOI: 10.1172/JCI112713. View

Chalasani N, Guo X, Loomba R, Goodarzi M, Haritunians T, Kwon S . Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010; 139(5):1567-76, 1576.e1-6. PMC: 2967576. DOI: 10.1053/j.gastro.2010.07.057. View

Dong H, Wang J, Li C, Hirose A, Nozaki Y, Takahashi M . The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol. 2007; 46(5):915-20. DOI: 10.1016/j.jhep.2006.12.012. View

Tran T, Changsri C, Shackleton C, Poordad F, Nissen N, Colquhoun S . Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J Gastroenterol Hepatol. 2006; 21(2):381-3. DOI: 10.1111/j.1440-1746.2005.03968.x. View

Malhi H, Gores G, Lemasters J . Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology. 2006; 43(2 Suppl 1):S31-44. DOI: 10.1002/hep.21062. View

10.

Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P . Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34(5):1139-44. PMC: 3114489. DOI: 10.2337/dc10-2229. View

11.

Szczepaniak L, Nurenberg P, Leonard D, Browning J, Reingold J, Grundy S . Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2004; 288(2):E462-8. DOI: 10.1152/ajpendo.00064.2004. View

12.

Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N . A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009; 41(5):591-5. DOI: 10.1038/ng.348. View

13.

Cobbold J, Anstee Q, Taylor-Robinson S . The importance of fatty liver disease in clinical practice. Proc Nutr Soc. 2010; 69(4):518-27. DOI: 10.1017/S0029665110001916. View

14.

Williams C, Stengel J, Asike M, Torres D, Shaw J, Contreras M . Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2010; 140(1):124-31. DOI: 10.1053/j.gastro.2010.09.038. View

15.

Struben V, Hespenheide E, Caldwell S . Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000; 108(1):9-13. DOI: 10.1016/s0002-9343(99)00315-0. View

16.

Anstee Q, McPherson S, Day C . How big a problem is non-alcoholic fatty liver disease?. BMJ. 2011; 343:d3897. DOI: 10.1136/bmj.d3897. View

17.

Speliotes E, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C . Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7(3):e1001324. PMC: 3053321. DOI: 10.1371/journal.pgen.1001324. View

18.

Hirschhorn J . Genomewide association studies--illuminating biologic pathways. N Engl J Med. 2009; 360(17):1699-701. DOI: 10.1056/NEJMp0808934. View

19.

Romeo S, Huang-Doran I, Baroni M, Kotronen A . Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010; 21(3):247-52. DOI: 10.1097/mol.0b013e328338ca61. View

20.

Wree A, Broderick L, Canbay A, Hoffman H, Feldstein A . From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013; 10(11):627-36. DOI: 10.1038/nrgastro.2013.149. View